BioMedNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Standing Distinct in Advancing Psychedelic Medicine

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) recently released financials and a business update for the third quarter ending Sept. 30, 2021. During this reporting period, the company filed three patent applications; successfully synthesized a novel psilocin analogue with improved pharmaceutical properties; launched Mindleap 2.0, an updated version of its proprietary virtual health platform; and completed its spin-out transaction of ALT House Cannabis Inc. “The highlight of this quarter was the five-year research agreement Mydecine Innovations entered with Johns Hopkins University School of Medicine… The agreement gives the company’s medical and scientific research teams the resources needed to explore things like different indications, enhanced delivery, improved dosing, shorter half-life or other improvements needed to advance understanding of these medicines in medical practice,” reads a recent article. “The research agreement is a good indication of the company’s commitment to advancing psychedelic medicine as a whole, since, unlike competitors, they are not just focusing on psilocybin of MDMA. ‘The long-term potential of this research agreement is captivating for use here at Mydecine,’ CSO and Co-Founder Rob Roscow stated. ‘It demonstrates our commitment to advancing psychedelic medicine by exploring multiple molecules and medicines for a variety of indications.’”

To view the full article, visit https://ibn.fm/zJvq9

About Mydecine Innovations Group

Mydecine Innovations is a biotechnology and digital technology company developing innovative first- and second-generation novel therapeutics for the treatment of mental health and addiction through world-class technology and drug-development infrastructure. Mydecine was founded in 2020 on the guiding principle that there is a significant unmet need and lack of innovation in the mental health and therapeutic treatment environments. Mydecine Innovations Group is dedicated to efficiently developing innovative therapeutics to treat PTSD, depression, anxiety, addiction and other mental health disorders. The company’s business model combines clinical trials and data outcome, technology, and scientific and regulatory expertise with a focus on psychedelic therapy underpinned by other novel molecules with differentiated therapeutic potential. By collaborating with some of the world’s foremost authorities connected by best practices, Mydecine Innovations Group aims to responsibly fast-track the development of new medicines across its platforms, seeking to effectively treat and ultimately change the way mental health disorders are treated. Mydecine’s vision is to bridge the current gap between what the mental health care system currently provides with the needs of the patients. Mydecine is headquartered in Denver, Colorado, USA, with international offices in Leiden, Netherlands. For more information about the company, please visit www.Mydecine.com.

NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork